SMi’s 10th Annual ADMET conference will provide essential insight into the latest novel technologies being used in the field of Predictive Toxicology and ADME/Tox. With drug induced liver and Cardiotoxicity still being major causes of drug attrition rates, the programme will feature case studies on development of human cellular models and state-of-the-art in vitro used to assess toxicity. This is a must attend event if you want to be at the forefront of pharmacokinetic/pharmacodynamic models; drug transporter assays in drug discovery; time-dependent inhibition screens in early drug discovery; the system-dependent inhibition of CYP enzymes and the integrating predictive toxicology framework.
Reasons why you should attend:
•In vitro models and technologies for detecting Cardiotoxicity
•Analyse performance of different in vitro models to detect human hepatotoxic drugs
•Human stem cell derived cardiomyocytes
•Regulatory DDI Guidance(s) for drug transporters - an overview review of current FDA, EMA and JMHLW (Japan) guidance for industry
•Mitigating errors in early human dose predictions and setting the criteria for ADME end points
Keynote speakers include:
•Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutical
•Professor Ian D. Wilson, Professor of Drug Metabolism, Imperial College London
•Laurent Salphati, Senior Scientist, Genentech
•Thierry Lave, Global Head DMPK & Tox Project Leaders and Modelling & Simulation, F. Hoffmann-La Roche
•Peter Clements, Director of Pathology, GSK
•Stephen Fowler, Group Leader, In Vitro ADME, F. Hoffmann-La Roche
•Franck Atienzar, Associate Director In Silico In Vitro Toxicology, UCB BioPharma SPRL
•Peter Hoffmann, Executive Director, Pre-Clinical Safety, Novartis Institutes for BioMedical Research
•Mario Monshouwer, Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis, Johnson & Johnson
In addition, don’t miss the post-conference workshop taking place on the 1st July:
• ADME(T) Strategies for Pharmacological Space Beyond Ro5 and Eukaryotic Enzyme Inhibitors
Workshop Leader: Constance Höfer, Chief Development Officer, Priaxon AG
HOW TO REGISTER
Register online using the book now button
Contact Magdalena Georgieva on +44 (0)20 7827 6148 or email mgeorgieva@smi-online.co.uk
Reasons why you should attend:
•In vitro models and technologies for detecting Cardiotoxicity
•Analyse performance of different in vitro models to detect human hepatotoxic drugs
•Human stem cell derived cardiomyocytes
•Regulatory DDI Guidance(s) for drug transporters - an overview review of current FDA, EMA and JMHLW (Japan) guidance for industry
•Mitigating errors in early human dose predictions and setting the criteria for ADME end points
Keynote speakers include:
•Araz Raoof, Head Scientific Affairs & Analysis, Janssen Pharmaceutical
•Professor Ian D. Wilson, Professor of Drug Metabolism, Imperial College London
•Laurent Salphati, Senior Scientist, Genentech
•Thierry Lave, Global Head DMPK & Tox Project Leaders and Modelling & Simulation, F. Hoffmann-La Roche
•Peter Clements, Director of Pathology, GSK
•Stephen Fowler, Group Leader, In Vitro ADME, F. Hoffmann-La Roche
•Franck Atienzar, Associate Director In Silico In Vitro Toxicology, UCB BioPharma SPRL
•Peter Hoffmann, Executive Director, Pre-Clinical Safety, Novartis Institutes for BioMedical Research
•Mario Monshouwer, Senior Director Drug Metabolism Pharmacokinetics & Bioanalysis, Johnson & Johnson
In addition, don’t miss the post-conference workshop taking place on the 1st July:
• ADME(T) Strategies for Pharmacological Space Beyond Ro5 and Eukaryotic Enzyme Inhibitors
Workshop Leader: Constance Höfer, Chief Development Officer, Priaxon AG
HOW TO REGISTER
Register online using the book now button
Contact Magdalena Georgieva on +44 (0)20 7827 6148 or email mgeorgieva@smi-online.co.uk
